Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon. 7. Juni 2016 Schuette, W., Dietel, M., Thomas, M., Eberhardt, W., Zirrgiebel, U., Radke, S., Schirmacher, P., 2016. Oncol Res Treat, 39 (suppl 1), (ID 0341) 120. doi:10.1159/000444354 Abstract Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial. Quidde, J., Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C., Killing, B., Depenbusch, R., Steffens, C.-C., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher, A., Tannapfel, A., Trarbach,… Weiterlesen REASON: Factors influencing outcome in patients (pts) with NSCLC stage IIIB/IV and mutated EGF receptor (EGFR-M+) treated with gefitinib. Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016. Oncol Res Treat, 39 (suppl 1) (ID 0345), 120. doi:10.1159/000444354… Weiterlesen